Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...

Merck’s diabetes drugs – Januvia and Janumet – are likely to see increased competition. The company’s animal health business is likely to benefit from increased pet ownership in the U.S ...

Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable on Wednesday, Jan. 8. That is over 5% more than the prior payout.

Merck & Co., Inc. operates as a healthcare company ... Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.